Equities research analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a research report issued on Saturday. The firm set a “hold” rating on the medical research company’s stock.
Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th.
Read Our Latest Research Report on Cytosorbents
Cytosorbents Stock Up 4.4 %
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. CM Management LLC boosted its position in shares of Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares in the last quarter. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents in the third quarter worth about $51,000. Finally, Geode Capital Management LLC boosted its stake in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.
Cytosorbents Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Featured Articles
- Five stocks we like better than Cytosorbents
- Best Aerospace Stocks Investing
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- What is a Special Dividend?
- These 3 Quirky ETFs May Be Strong Plays in 2025
- How to Use the MarketBeat Dividend Calculator
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.